Company news
Kyverna Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
November 13, 2024
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 12, 2024
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
October 20, 2024
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
September 17, 2024
Kyverna Therapeutics Announces Leadership Update
September 15, 2024
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
August 20, 2024
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
August 11, 2024
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 11, 2024
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
July 14, 2024
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
June 19, 2024
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
June 16, 2024
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
June 9, 2024
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
June 6, 2024
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 13, 2024
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
April 10, 2024
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
March 28, 2024
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
March 25, 2024
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
March 6, 2024
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 11, 2024
Decks
The 5 newest of 11 decks. Every deck is listed under its year.
- Investor Presentation (October 2026)
Investor deck · 37 slides · October 2026
- Corporate Update (September 2026)
Corporate update · 29 slides · Sep 24, 2026
- Investor Presentation (September 2026)
Investor deck · 37 slides · September 2026
- Jefferies Healthcare Conference 2026
Conference · 31 slides · June 2026
- AAN 2026 Annual Meeting
Conference · 38 slides · Apr 22, 2026